Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

human ovarian cancer cell lines

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BCRP (1) Apoptosis (5) Bcl-2 Family (2) Caspase (2) CDK (2) COX (1) Cyclophilin (1) Drug Derivative (1) Endothelin Receptor (1) Fluorescent Dye (1) HCV (1) HDAC (1) Interleukin Related (1) Lipoxygenase (1) Microtubule/Tubulin (1) MMP (1) NEKs (1) NF-κB (1) P-glycoprotein (2) Phosphatase (1) Poly(ADP-ribose) Glycohydrolase (PARG) (1) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (1) TMV (1) TNF Receptor (1) TROP2 (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (1) Endocrinology (1) Inflammation/Immunology (2) Metabolic Disease (1)

By Targets:

BCRP (1)

Apoptosis (5)

Bcl-2 Family (2)

Caspase (2)

CDK (2)

COX (1)

Cyclophilin (1)

Drug Derivative (1)

Endothelin Receptor (1)

Fluorescent Dye (1)

HCV (1)

HDAC (1)

Interleukin Related (1)

Lipoxygenase (1)

Microtubule/Tubulin (1)

MMP (1)

NEKs (1)

NF-κB (1)

P-glycoprotein (2)

Phosphatase (1)

Poly(ADP-ribose) Glycohydrolase (PARG) (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (ROS) (1)

TMV (1)

TNF Receptor (1)

TROP2 (1)

By Research Areas:

Cancer (16)

Cardiovascular Disease (1)

Endocrinology (1)

Inflammation/Immunology (2)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122639

ZINC05007751 3 Publications Verification	NEKs	Cancer
ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC₅₀ of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 .

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .

HY-B1022

Dimesna 1 Publications Verification BNP-7787	Drug Derivative	Endocrinology Cancer
Dimesna (BNP-7787), the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna does not interfere with the antitumor activity of platinum compounds. Dimesna does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna counteracts Cisplatin-induced nephrotoxicity. Dimesna exerts selective protective effects on the kidneys. Dimesna can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .

HY-P99413

IMAB027 ASP1650	HCV	Cancer
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 ⁺ ovarian and testicular cancer cell lines .

HY-P2496

Endothelin 1 (swine, human), Alexa Fluor 488-labeled	Endothelin Receptor Fluorescent Dye NF-κB COX Prostaglandin Receptor Apoptosis TNF Receptor Interleukin Related MMP	Cardiovascular Disease Inflammation/Immunology Cancer
Endothelin 1 (swine, human), Alexa Fluor 488-labeled is an Endothelin-1 conjugated with Alexa Fluor 488 (HY-D1304). Endothelin-1 is an endogenous vasoconstrictor and agonist of ETA/ETB receptor. Endothelin 1 (swine, human) exerts effects including promoting mitosis, angiogenesis, tumor invasion and metastasis, and inhibiting apoptosis. Endothelin 1 (swine, human) induces inflammation and oxidative stress by activating the NF-κB pathway. Endothelin 1 (swine, human), Alexa Fluor 488-labeled is specifically designed for fluorescence imaging, flow cytometry or receptor localization studies, and can be used in research related to sepsis, atherosclerosis, systemic inflammatory response syndrome, cancer and congestive heart failure .

HY-117085

Lobaric acid	Phosphatase TMV Lipoxygenase	Cancer
Lobaric acid is a depsipeptide metabolite isolated from Stereocaulon lichen with antioxidant, antiproliferative, antiviral and enzyme inhibitory activities. Lobaric acid scavenges superoxide free radicals (IC₅₀=97.9 μM) and inhibits cancer cell proliferation (EC₅₀ of 15.2-63.9 μg/mL against leukemia, colorectal, gastric, breast, ovarian, prostate, pancreatic and lung cancer cell lines). Lobaric acid inhibits protein tyrosine phosphatase 1B (PTP1B; IC₅₀=0.87 μM for human recombinant enzyme) and 12(S)-HETE produced by 12(S)-lipoxygenase (IC₅₀=28.5 μM). Lobaric acid (250 μM) also reduced pathological changes in tobacco leaves infected with tobacco mosaic virus (TMV).

HY-175857

HDAC-IN-92	HDAC Apoptosis	Cancer
HDAC-IN-92 is a pan-HDAC inhibitor with an IC₅₀ of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM). HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor .

HY-123034

CDKI-83	CDK Bcl-2 Family Apoptosis	Cancer
CDKI-83 is a potent CDK9 and CDK1 inhibitor with K_i values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI₅₀<1 μM. CDKI-83 effectively induces apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research .

HY-182397

ZX-J-19L	Cyclophilin	Cancer
ZX-J-19L is a CyPJ inhibitor with inhibitory activity against a variety of tumor cell lines. ZX-J-19L inhibits the growth of human liver cancer cells, human breast cancer cells, ovarian cancer cells and prostate cancer cells in vitro. ZX-J-19L can be used for tumor research .

HY-N19463

Dicatenarin	Caspase Reactive Oxygen Species (ROS) Apoptosis	Cancer
Dicatenarin is a caspase‑3 activator with growth‑inhibitory activity against human cancer cells. Dicatenarin increases caspase‑3 activity, induces intracellular ROS generation, and activates the mitochondrial‑mediated apoptotic pathway. Dicatenarin exerts growth‑inhibitory effects against a panel of human cancer cell lines. Dicatenarin can be used in research on pancreatic cancer, lung cancer, colon cancer, breast cancer, prostate cancer, and ovarian cancer .

HY-141425

NSC73306	P-glycoprotein	Cancer
NSC73306, a thiosemicarbazone, is a cell penetrant, cytotoxic agent that exhibits greater toxicity against cells expressing functional P-gp (P-glycoprotein) than against other cells .

HY-164717

FORX-428	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
FORX-428 is a selective and orally active Poly (ADP-ribose) glycohydrolase (PARG) inhibitor. FORX-428 exhibits strong and reversible binding to the catalytic domain of human PARG, and thereby inhibits PARG´s enzymatic activity. FORX-428 leads to the excessive accumulation of PAR chains and activates DNA damage and replication stress responses. FORX-428 selectively inhibits the proliferation of various cancer cell lines, including breast, ovarian, and gastric cancer .

HY-181565

CDK7-IN-33	CDK	Metabolic Disease Inflammation/Immunology Cancer
CDK7-IN-33 is an orally active pyrimidine derivative and also a CDK7 kinase inhibitor. CDK7-IN-33 is applicable to the research of cancer, inflammation, cardiovascular diseases, infectious diseases, immune diseases and metabolic diseases .

HY-N18126

13b,14-Dihydrorutaecarpine	Others	Cancer
13b,14-Dihydrorutaecarpine is a cytotoxin derived from dihydrorutaecarpine. 13b,14-Dihydrorutaecarpine exerts selective cytotoxicity against central nervous system (CNS) and prostate cancer cell lines (GI₅₀=0.02 μM and 0.2 μM). 13b,14-Dihydrorutaecarpine can be used in the research of central nervous system (CNS) cancer, ovarian cancer, prostate cancer and renal cancer .

HY-13774

WK-X-34	P-glycoprotein BCRP	Cancer
WK-X-34 is a low-toxicity, highly effective multidrug resistance reversal agent. By potently inhibiting the transport functions of P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP), WK-X-34 significantly increases the intracellular accumulation of anticancer drugs and radiotracers in drug-resistant cells. WK-X-34 exerts no significant effect on MRP transporters. WK-X-34 not only restores the chemosensitivity of multidrug-resistant ovarian cancer cells, but also significantly enhances the uptake of ^99mTc-Sestamibi in P-gp-positive xenograft tumors, brain and intestinal tissues. WK-X-34 exhibits extremely low toxicity and favorable safety profiles both in vitro and in mice (at doses up to 50 mg/kg), and can be used for research on overcoming multidrug resistance in ovarian cancer .

HY-136893

SP-6-27	Microtubule/Tubulin Apoptosis Caspase Bcl-2 Family	Cancer
SP-6-27 is a tubulin depolymerizing agent that binds to the colchicine site of β-tubulin. SP-6-27 induces G₂/M cell cycle arrest in ovarian cancer cells. SP-6-27 enhances intrinsic apoptosis in ovarian cancer cells through upregulation of Bax, Apaf-1, caspase-6, caspase-9, and caspase-3. SP-6-27 reduces ovarian cancer cell migration. SP-6-27 inhibits capillary tube formation by human umbilical vein endothelial cells. SP-6-27 shows minimum cytotoxicity to normal ovarian epithelia. SP-6-27 shows enhanced cytotoxicity in chemo-sensitive/resistant ovarian cancer cells when combined with Cisplatin (HY-17394). SP-6-27 can be used for the research of ovarian cancer .

Cat. No.	Product Name	Target	Research Area